Resource Center

Go back to Resource Center

Determining Population and Developmental Pharmacokinetics of Metronidazole using Plasma and Dried Blood Spot Samples from Premature Infants

2013 Sep

Journal Article

Authors:
Cohen-Wolkowiez, M.; Sampson, M.; Bloom, B.T.; Arrieta, A.; Wynn, J.L.; Martz, K.; Harper, B.; Kearns, G.L.; Capparelli, E.V.; Siegel, D.; Benjamin, D.K.; Smith, B.

Secondary:
Pediatr Infect Dis J

Volume:
32

Pagination:
956-61

Issue:
9

PMID:
23587979

DOI:
10.1097/INF.0b013e3182947cf8

Keywords:
Anti-Infective Agents; Blood Chemical Analysis; BPCA; Desiccation; Female; Humans; Infant; Infant, Newborn; Infant, Premature; Male; Metronidazole; Models, Theoretical; Prospective Studies; Specimen Handling

Abstract:
BACKGROUND: Limited pharmacokinetic (PK) data of metronidazole in premature infants have led to various dosing recommendations. Surrogate efficacy targets for metronidazole are ill-defined and therefore aimed to exceed minimum inhibitory concentration of organisms responsible for intra-abdominal infections.METHODS: We evaluated the PK of metronidazole using plasma and dried blood spot samples from infants ≤32 weeks gestational age in an open-label, PK, multicenter (N = 3) study using population PK modeling (NONMEM). Monte Carlo simulations (N = 1000 virtual subjects) were used to evaluate the surrogate efficacy target. Metabolic ratios of parent and metabolite were calculated.RESULTS: Twenty-four premature infants (111 plasma and 51 dried blood spot samples) were enrolled: median (range) gestational age at birth 25 (23-31) weeks, postnatal age 27 (1-82) days, postmenstrual age 31 (24-39) weeks and weight 740 (431-1466) g. Population clearance (L/h/kg) was 0.038 × (postmenstrual age/30) and volume of distribution (L/kg) of 0.93. PK parameter estimates and precision were similar between plasma and dried blood spot samples. Metabolic ratios correlated with clearance.CONCLUSION: Simulations suggested the majority of infants in the neonatal intensive care unit (>80%) would meet the surrogate efficacy target using postmenstrual age-based dosing.

Go back to Resource Center